💨 Abstract

The U.S. FDA has approved Eli Lilly's new GLP-1 weight-loss pill, Foundayo, for adults with obesity or weight-related medical issues. The oral pill, to be taken daily alongside diet and exercise, showed significant weight loss in trials. The approval process was notably swift. The drug's common side effects include nausea, constipation, and potential thyroid tumors. Previous studies have linked GLP-1 drugs to risks like stomach paralysis and vision loss.

Courtesy: Uday Rana